Pentraxin-3 and Outcomes in CKD: A Systematic Review and Meta-analysis.

RATIONALE & OBJECTIVE: Long pentraxin-3 (PTX-3) serves as a biomarker for prognosticating adverse clinical outcomes in individuals with chronic kidney disease (CKD). The objective of the current meta-analysis was to evaluate the prognostic efficacy of PTX-3 in patients with CKD. In addition, we compared the prognostic effectiveness of PTX-3 and the short pentraxin C-reactive protein (CRP) in the identical cohort of patients with CKD.

STUDY DESIGN

A systematic review and meta-analysis.

SETTING & PARTICIPANTS: Patients with CKD treated with or without dialysis.

SELECTION CRITERIA FOR STUDIES

A cohort study with a minimum 1-year follow-up.

DATA EXTRACTION

Risk measurements, adjusted hazard risk with 95% CI, and modified variables.

ANALYTICAL APPROACH

To aggregate the adjusted effect estimates, a fixed-effects or random-effects model was employed.

RESULTS

Nine studies covering 1,825 patients with CKD were selected in the present review. Six of the 9 studies exclusively included patients receiving hemodialysis. The collected findings indicated that patients with CKD in the highest tertile of PTX-3 demonstrated significantly higher risks of all-cause mortality (HR, 1.92; 95% CI, 1.44-2.56), cardiovascular death (HR, 1.98; 95% CI, 1.28-3.05), infectious death (HR, 5.26; 95% CI, 1.60-17.31), and fatal and nonfatal cardiovascular events (HR, 1.81; 95% CI, 1.35-2.42), as compared with those in the lowest tertile. These significant associations with risk were also observed when effect estimates were presented as per unit change in the PTX-3. Moreover, when comparing the prognostic value of PTX-3 and CRP in the same individuals (5 studies covering 904 patients), PTX-3 proved to be a satisfactory predictor of adverse events in these patients, whereas CRP failed to exhibit such predictive capability, regardless of the type of effect estimate used.

LIMITATIONS

A relatively small sample size and some heterogeneity.

CONCLUSIONS

Pentraxin 3 is associated with adverse events in individuals with CKD and may be a more reliable predictor of adverse clinical events than CRP in this population.